DIVISION OF

CORPORATION FINANCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

Mail Stop 3561

November 30, 2016

Via E-mail David J. Mazzo, Ph.D. Chief Executive Officer Caladrius Biosciences, Inc. 106 Allen Road, Fourth Floor Basking Ridge, NJ 07920

> Re: Caladrius Biosciences, Inc.

> > **Registration Statement on Form S-3**

Filed November 15, 2016

File No. 333-214607

Dear Dr. Mazzo:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jonathan Burr at (202) 551-5833 with any questions.

Sincerely,

/s/ Pamela Howell

for

John Reynolds **Assistant Director** Office of Beverages, Apparel, and

Mining

Jeffrey P. Schultz, Esq. cc:

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.